Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (Nasdaq: LFMD) is a virtual primary care and pharmacy company whose news flow centers on telehealth expansion, clinical program development, strategic collaborations, and capital markets activity. As a provider of virtual healthcare services across more than 200 conditions, LifeMD regularly issues updates on its weight management, women’s health, men’s health, behavioral health, and primary care offerings, as well as on its pharmacy and compounding pharmacy capabilities.
News about LifeMD often highlights clinical and commercial partnerships, particularly in obesity and metabolic health. The company has announced an expanded collaboration with Novo Nordisk, under which LifeMD is recognized as a telehealth partner offering FDA-approved GLP‑1 therapies such as Wegovy and Ozempic. Press releases describe new product availability, including the Wegovy oral pill, and cash-pay pricing initiatives designed to broaden access to branded GLP‑1 medications through LifeMD’s virtual weight management programs.
Investors and observers can also expect financial and corporate updates in LifeMD’s news stream. These include quarterly earnings releases, segment performance commentary, and disclosures about strategic transactions such as the divestiture of its majority interest in WorkSimpli Software LLC. The company’s transition into a pure-play virtual care and pharmacy platform, along with its efforts to strengthen its balance sheet, are recurring themes in management commentary.
Additional news items cover capital structure and governance developments, such as the authorization of dividends on the company’s 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and the establishment of a senior secured revolving credit facility with Citizens Bank, N.A. Regulatory and reporting updates, including Forms 8‑K and notifications of late filings related to financial statement adjustments, also appear in the company’s announcements.
For those following LFMD, this news page provides a centralized view of LifeMD’s earnings reports, clinical program launches, partnership expansions, financing arrangements, and regulatory disclosures, offering context on how the company is evolving its virtual care and pharmacy platform over time.
LifeMD, Inc. (NASDAQ: LFMD), a prominent telehealth provider, announced its participation in the 21st Annual Needham Virtual Healthcare Conference scheduled for April 11-14, 2022. The company will present on April 13 at 3:00 PM ET and will offer one-on-one meetings for investors. LifeMD provides a wide range of telehealth services across all 50 states, focusing on primary care, diagnostics, and specialized treatments. The company's goal is to enhance access to affordable healthcare through its technology platform and mail-order pharmacy network.
LifeMD, Inc. (NASDAQ: LFMD/LFMDP) has declared a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock. This dividend will be payable on April 15, 2022, to shareholders on record as of April 5, 2022. The company leverages its telehealth platform to enhance healthcare access and affordability across the United States, catering to various health conditions. LifeMD remains committed to expanding its services and outreach within the telehealth sector.
On March 23, 2022, LifeMD, Inc. (NASDAQ: LFMD) launched NavaMD™, a clinically studied OTC skincare line designed for women, incorporating over 35 patents and proprietary enzyme technology, Aquabeautine XL®. This innovative product line includes a cleanser, serum, moisturizer, and eye cream, all dermatologist-tested and suitable for various skin types. LifeMD aims to enhance telehealth offerings while ensuring personalized skincare solutions. The company's strategy continues to focus on expanding proprietary products in dermatology, leveraging its telehealth platform and expert medical team.
LifeMD, Inc. (NASDAQ: LFMD) announced its participation in the KeyBanc Virtual Healthcare Conference on March 22-23, 2022. CFO Marc Benathen will present on March 22 at 3:45 PM EST. LifeMD is a telehealth company operating across 50 states, focusing on virtual primary care, diagnostics, and specialized treatments.
This participation highlights their commitment to enhancing healthcare access through innovative technology and a nationwide mail-order pharmacy network. For registration inquiries, please contact KeyBanc's sales representatives.
LifeMD, Inc. (NASDAQ: LFMD) reported a 149% increase in FY2021 revenue, totaling $92.9 million, with fourth quarter revenue reaching $27.4 million, up 113%. The fourth quarter Adjusted EPS improved 19% sequentially to $(0.29). The company achieved record gross margins of 81% and improved cash flow by 21% sequentially. With over $41 million in cash and no debt, FY2022 revenue guidance is between $142 million and $148 million, aiming for Adjusted EBITDA profitability by Q4 2022.
LifeMD, Inc. (NASDAQ: LFMD) announced it will release its financial results for the year ending December 31, 2021, on March 7, 2022, after market close. The company will hold a conference call at 4:30 PM ET to discuss these results and provide a corporate update. LifeMD is a growing telehealth company offering virtual care across 50 states, utilizing a proprietary tech platform and pharmacy network to enhance healthcare accessibility.
LifeMD announced the nationwide launch of its virtual primary care platform, providing 24/7 access to affordable healthcare across all 50 states. This platform enables patients to connect with top-quality doctors through a simple three-step process: completing a health questionnaire, a virtual consultation, and ongoing access to care. With significant investments in technology and strategic partnerships, LifeMD aims to enhance healthcare access and efficiency. Previously available in beta, the platform targets the 25% of U.S. adults lacking a primary care physician.
LifeMD, Inc. (NASDAQ: LFMD) will hold its first Analyst and Investor Day on February 22, 2022, from 1:30 p.m. to 3 p.m. ET. The virtual event will feature executives discussing the company's telehealth opportunities, growth strategies, and financial outlook. LifeMD aims to strengthen its position in the telehealth market, leveraging its newly acquired allergy and asthma business and its Virtual Primary Care platform. With a record of over 427,000 patients treated and FY 2021 revenues of $92.9 million (up 149%), LifeMD is on track for adjusted EBITDA profitability by Q4 2022.
LifeMD, a prominent telehealth company, will participate in two key conferences: the SVB Leerink Global Healthcare Conference from February 16-18, 2022, and Citi’s Virtual Healthcare Conference on February 23-24, 2022. Interested parties can request one-on-one meetings at the SVB conference via a provided link. LifeMD offers accessible telehealth services across 50 states, focusing on various healthcare needs through its advanced technology platform and nationwide pharmacy network. For more information, visit LifeMD.com.
LifeMD, Inc. (NASDAQ: LFMD) anticipates FY2022 revenue between $142 million and $148 million, reflecting a robust year-over-year growth of 149% with a fourth quarter revenue of $27.4 million. The company aims to achieve Adjusted EBITDA profitability by Q4 2022. CEO Justin Schreiber highlighted increasing demand for telehealth services and the launch of LifeMD Virtual Primary Care. CFO Marc Benathen noted progress in reducing cash burn and maintaining liquidity to support growth initiatives.